<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01939054</url>
  </required_header>
  <id_info>
    <org_study_id>BT-BC-001</org_study_id>
    <nct_id>NCT01939054</nct_id>
  </id_info>
  <brief_title>Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients</brief_title>
  <official_title>A Randomized, Controlled, Open-Label, Multicenter, Phase 2 Study of Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine as First-Line Treatment in Patients With Recurrent/Metastatic Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotech Pharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in
      the extra cellular domain of the human epidermal growth factor receptor (EGFR), inhibiting
      tyrosine kinase activation. This is a randomized, controlled, open-Label, multicenter, phase
      Ⅱ clinical trial of nimotuzumab plus Docetaxel and Capecitabine（TX）versus Docetaxel and
      Capecitabine（TX）as first-line treatment in patients with recurrent/metastatic triple negative
      breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The control group received docetaxel + capecitabine regimen;Experimental group received
      Nimotuzumab combined docetaxel + capecitabine regimen.The main purpose is to evaluate
      Nimotuzumab Plus Docetaxel and Capecitabine（TX）as First-Line Treatment in Patients With
      Recurrent/Metastatic triple negative breast cancer would improve objective response rate (ORR
      ) comparing with Docetaxel and Capecitabine（TX）.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>every six weeks, up to 1 year</time_frame>
    <description>Evaluation ORR every six weeks,with RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>every six weeks, up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and ratio of AEs</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Observe and record AEs when AEs occurred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of tissue/serum EGFR between efficacy and prognosis</measure>
    <time_frame>1 year</time_frame>
    <description>every 6 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab,docetaxel,capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>docetaxel,capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <arm_group_label>Nimotuzumab,docetaxel,capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>Nimotuzumab,docetaxel,capecitabine</arm_group_label>
    <arm_group_label>docetaxel,capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>Nimotuzumab,docetaxel,capecitabine</arm_group_label>
    <arm_group_label>docetaxel,capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological and immunohistochemistry (IHC) confirmed recurrent or metastatic
             triple-negative breast cancer .

          2. Previous chemotherapy should include anthracycline or taxane; No prior chemotherapy
             after metastasis.

          3. Females with age between 18 and 70 years old

          4. ECOG performance status 0 or 1.

          5. At least one measurable disease according to the response evaluation criteria in solid
             tumor (RECIST) by magnetic resonance imaging, or computed tomography; The target
             lesions is Unresectable; The target lesions did not receive radiotherapy or relapse
             within the radiation field;

          6. Life expectancy ≥ 12 weeks.；

          7. WBC count ≥ 4 × 109 / L, neutrophils ≥ 1.5 × 109 / L, platelet count ≥ 100 × 109 / L,
             hemoglobin ≥ 6.21mmol / L (10 g / dL);

          8. Total bilirubin (TBL)≤ 1.5 x ULN (upper limit of normal reference values); AST and ALT
             ≤ 2.5 x ULN or ≤ 5 ULN (Liver metastasis);Serum creatinine ≤ 1.5 x ULN.

          9. Before enrollment, patients have fully recovered from previous treatment-related
             toxicity;

         10. Subjects with fertility must accept effective contraceptive measures;

         11. Signed informed consent

        Exclusion Criteria:

          1. Previously treatment regimen including anti EGFR monoclonal antibody;

          2. Receiving other anti-cancer medicine treatment during the study

          3. Participate in other clinical trials within 4 weeks in this group;

          4. Accepted taxane treatment in 1 year;

          5. Presence of neurological symptoms due to brain metastasis, patients receiving
             steroidal anti-edema drugs therapy;

          6. Patients having a history of clinically significant symptomatic angina, arrhythmia or
             congestive heart failure without control;

          7. Diagnosed with severe interstitial pneumonitis or pulmonary fibrosis by chest CT;

          8. Pleural effusion, ascites require to be drained;

          9. Adverse drug addiction and drug abuse, long-term alcoholics, as well as AIDS patients;
             patients with severe or uncontrolled complications, such as infection requiring
             systemic therapy, fever (≥ 38 ℃), diabetes or hypertension can not be controlled by
             medicine, other complications may interfere with drug therapy;

         10. Patients with a history of drug allergy (≥ CTCAE 2 level) such as shock or allergic
             symptoms, especially have allergic reactions to similar drugs in the past, have severe
             allergies reactions to drugs containing polysorbate eighty (Tween 80);

         11. Uncontrolled seizures or loss of insight due to mental disorders;

         12. Pregnant or lactating women；

         13. Researchers think improper for this trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binghe Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Insititute and Hospital, CAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Binghe Xu</last_name>
    <phone>86-10-88788826</phone>
    <email>xubinghe@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peng Yuan</last_name>
    <phone>86-10-8778 8114</phone>
    <email>yuanpeng01@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binghe Xu, M.D.</last_name>
      <phone>86-10-88788826</phone>
      <email>xubinghe@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Peng Yuan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing cancer hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>huiping Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The General Hospital of the People's Liberation Army (PLAGH)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>junlan yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>li cai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital and Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>tao sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>FuDan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>xichun Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi-an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>rui ling</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of College of Medicine, Zhejiang University (First Hospital of Zhejiang Province)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>peifen fu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>xiaojia wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2013</study_first_submitted>
  <study_first_submitted_qc>September 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2013</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Binghe Xu</investigator_full_name>
    <investigator_title>Director of Medical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

